Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

T24 bladder cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Akt (5) AMPK (1) Apoptosis (6) Arf Family GTPase (1) ATP Synthase (1) Autophagy (2) Bcl-2 Family (1) BMX Kinase (1) Caspase (2) CDK (1) COX (2) Cytochrome P450 (2) ERK (2) Ferroptosis (4) Glutathione Peroxidase (1) Glycosidase (2) Histone Methyltransferase (2) IAP (2) Insulin Receptor (2) JNK (2) NO Synthase (2) p38 MAPK (2) Photosensitizer (1) PI3K (2) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (2) ROS Kinase (1) SARS-CoV (1) Survivin (2)
By Research Areas:	Cancer (18) Infection (1) Inflammation/Immunology (2) Metabolic Disease (3)

By Targets:

ADC Antibody (1)

Akt (5)

AMPK (1)

Apoptosis (6)

Arf Family GTPase (1)

ATP Synthase (1)

Autophagy (2)

Bcl-2 Family (1)

BMX Kinase (1)

Caspase (2)

CDK (1)

COX (2)

Cytochrome P450 (2)

ERK (2)

Ferroptosis (4)

Glutathione Peroxidase (1)

Glycosidase (2)

Histone Methyltransferase (2)

IAP (2)

Insulin Receptor (2)

JNK (2)

NO Synthase (2)

p38 MAPK (2)

Photosensitizer (1)

PI3K (2)

PROTACs (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (2)

ROS Kinase (1)

SARS-CoV (1)

Survivin (2)

By Research Areas:

Cancer (18)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108719

Insulin glargine 1 Publications Verification	Insulin Receptor Akt	Metabolic Disease Cancer
Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .

HY-N2420

Flavokawain A 2 Publications Verification	Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt	Inflammation/Immunology Cancer
Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .

HY-P99899

Samrotamab PR-1498487	ADC Antibody	Cancer
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085 .

HY-171030

Pro-GA	Reactive Oxygen Species (ROS)	Cancer
Pro-GA is a γ-glutamyl cyclotransferase (GGCT) inhibitor. Pro-GA inhibits the enzymatic activity of GGCT, disrupts glutathione homeostasis, induces the production of mitochondrial ROS, and upregulates the expression of p21, p27 and p16 in cells. Pro-GA inhibits the growth of cancer cells, induces cell cycle arrest and cellular senescence. Pro-GA exerts anti-tumor effects in breast cancer xenograft mouse models. Pro-GA can be used in research related to bladder cancer and breast cancer .

HY-174086

PROTAC GPX4 degrader-4	Glutathione Peroxidase Ferroptosis ROS Kinase PROTACs	Cancer
PROTAC GPX4 degrader-4 is a GPX4 PROTAC degrader (DC₅₀: 5.32 nM). PROTAC GPX4 degrader-4 inhibits the activity of RT4, T24, and J82 cancer cells (IC₅₀ values are 0.09, 2.97, and 7.58 μM, respectively). PROTAC GPX4 degrader-4 increases lipid ROS levels and induces ferroptosis in T24 and RT4 cells. PROTAC GPX4 degrader-4 has antitumor activity in T24 tumor-bearing BALB/c nude mouse model. PROTAC GPX4 degrader-4 can be used for bladder cancer research. (Pink: target protein ligand (HY-N0193); blue: E3 ligase ligand (HY-1035960); black: linker (HY-W013907); E3 ligase ligand + linker (HY-174087)) .

HY-141649

Anticancer agent 251	Apoptosis Autophagy Ferroptosis	Cancer
Anticancer agent 251 (compound 7j) can induce cell death of bladder cancer cell T24 by inducing apoptosis, autophagy or ferroptosis .

HY-113636

Kazinol A	Apoptosis Autophagy Akt AMPK	Cancer
Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .

HY-173280

Brefeldin A 4-O-nicotinate CHNQD-01228	Arf Family GTPase BMX Kinase	Cancer
Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins. The IC₅₀ value for the proliferation of T24 cells is 0.22 μM. It can also dose-dependently inhibit the migration and colony formation of T24 cells, induce G1 phase arrest and trigger Apoptosis. Brefeldin A 4-O-nicotinate exerts its anti-cancer activity by targeting the BMX protein to inhibit the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, as well as by inhibiting the Arf1 protein to eliminate bladder cancer stem cells and activate anti-tumor immunity. Brefeldin A 4-O-nicotinate can be used in the research related to bladder cancer .

HY-161341

β-Glucuronidase responsive conjugate 1	Photosensitizer	Cancer
β-Glucuronidase responsive conjugate 1 (compound 3) is a well-balanced photosensitizer which has photodynamic activity. β-Glucuronidase responsive conjugate 1 inhibits T-24 cell viability and growth with an IC₅₀ of 0.2 μM. β-Glucuronidase responsive conjugate 1 can used to study bladder cancers .

HY-173473

Anticancer agent 272	Reactive Oxygen Species (ROS) Apoptosis Ferroptosis	Cancer
Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC₅₀: 2.81 μM). Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (?OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer .

HY-N2420R

Flavokawain A (Standard)	Reference Standards Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt	Inflammation/Immunology Cancer
Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .

HY-N15348

Aphidicolins B32	Others	Cancer
Aphidicolins B32 is a diterpenoid compound discovered in the marine fungus Botryotinia fuckeliana, exhibiting cytotoxic activity against human bladder cancer cells. It inhibits the proliferation of T24 cells in the G0/G1 phase, with an IC₅₀ of 27.6 μM. Aphidicolins B32 holds potential for research in the field of cancer therapy .

HY-169406

α-Glucosidase-IN-76	Glycosidase	Cancer
α-Glucosidase-IN-76 (Compound 4r) is an inhibitor for α-glucosidase with an IC₅₀ of 5.44 μM. α-Glucosidase-IN-76 scavenges ABTS+ free radicals with a TEAC value of 0.49. α-Glucosidase-IN-76 inhibits the proliferation of T24 bladder cancer cell with IC₅₀ of 1.74 μM .

HY-108719R

Insulin glargine (Standard)	Reference Standards Insulin Receptor Akt	Metabolic Disease Cancer
Insulin glargine (Standard) is the analytical standard of Insulin glargine (HY-108719). This product is intended for research and analytical applications. Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .

HY-181489

SARS-CoV-2 3CLpro-IN-35	SARS-CoV	Infection Cancer
SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC₅₀ of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer .

HY-183312

Antitumor agent-217	ATP Synthase Reactive Oxygen Species (ROS) Bcl-2 Family Apoptosis Ferroptosis	Cancer
Antitumor agent-217 is a dual mitochondria-targeted anticancer agent. Antitumor agent-217 exhibits potent and selective antiproliferative activity against bladder cancer cell line J82 (IC₅₀ = 6.3 μM), and inhibits colony formation and migration of J82 cells. Antitumor agent-217 accumulates in mitochondria, alters mitochondrial morphology, reduces ATP production, increases ROS generation and decreases mitochondrial membrane potential. Antitumor agent-217 induces apoptosis (Apoptosis) and ferroptosis (Ferroptosis) in bladder cancer cells. Antitumor agent-217 can be used for the research of bladder cancer .

HY-181353

α-Glucosidase-IN-112	Glycosidase	Metabolic Disease Cancer
α-Glucosidase-IN-112 is an α-glucosidase inhibitor with an IC₅₀ of 2.03 μM and a K_i of 0.44 μM. α-Glucosidase-IN-112 exerts antioxidant effects by scavenging ABTS ⁺ free radicals. α-Glucosidase-IN-112 exerts antiproliferative effects by inhibiting the proliferation of bladder cancer cells. α-Glucosidase-IN-112 can be used in research related to type 2 diabetes and bladder cancer .

HY-183297

CDK4-IN-5	CDK	Cancer
CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G₀/G₁ phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer .

Cat. No.	Product Name	Target	Research Area